edp-514
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 26, 2019 (NCT04008004)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Hepatitis B virusINHIBITOR
Hepatitis B virus inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04971512 | Phase 1 | Aug 2, 2021 | Enanta Pharmaceuticals |
| NCT04783753 | Phase 1 | Nov 5, 2020 | Enanta Pharmaceuticals, Pharmaceutical Research Associates, Inc. (PRA) |
| NCT04470388 | Phase 1 | Sep 9, 2020 | Enanta Pharmaceuticals, Pharmaceutical Research Associates, Inc. (PRA) |
| NCT04008004 | Phase 1 | Jun 26, 2019 | Enanta Pharmaceuticals, Pharmaceutical Research Associates, Inc. (PRA) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Enanta Pharmaceuticals | For profit | 4 | 4 | 1 | 2019 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 3 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1